HDAC INHIBITION BLUNTS ISCHEMIA/REPERFUSION INJURY BY NORMALIZING CARDIOMYOCYTE AUTOPHAGY

Whereas reperfusion injury accounts for up to 50% of the injury of ischemia/reperfusion (I/R), no therapies are available targeting this. Histone deacetylases (HDAC) inhibitor reduces infarct size by 50% in mouse I/R models. Translating these results to human, however, requires large animal testing